Navigation Links
MimiVax Appoints Jerry Jacobs Jr. to Board of Directors; SurVaxM Immunotherapy Partnership Opportunities at BIO International June 19-22, 2017.
Date:6/12/2017

MimiVax, LLC, a cancer immunotherapy company today announced that Jerry Jacobs, Jr, co-CEO of Delaware North has joined its Board of Directors. Mr. Jacobs brings deep entrepreneurial insights and business resources to the company.

Mr. Jacobs is co-CEO of Delaware North, one of the most admired family-owned and operated companies in the world. Delaware North is headquartered in Buffalo, New York and has annual revenues of $3 billion, employing more than 55,000 employees on four continents. The University at Buffalo medical school was recently named the Jacobs School of Medicine and Biomedical Sciences, in recognition of the Mr. Jacobs family’s steadfast support.

MimiVax’s lead immunotherapeutic agent, SurVaxM, is currently in a Phase II multicenter clinical trial, and a recently completed interim data analysis puts the program in great position for continued advancement. MimiVax is looking forward to Mr. Jacobs’ strategic guidance for the company and helping it progress much needed new therapies for brain cancer patients.

MimiVax executives will be discussing partnering opportunities for its lead program SurVaxM, as well as pre-clinical pipeline assets: novel anti-survivin monoclonal antibody and CAR-T based approaches for solid tumors at the annual BIO International Conference, taking place between June 19-22, 2017 at the San Diego Convention Center.

Michael Ciesielski, PhD, Chief Scientific Officer; and Anil Goyal, PhD, VP Business Development will be attending the BIO event and hosting partnership meetings.

BIO International Conference : (http://www.bio.org)
Monday-Thursday June 19-22, 2017 ; San Diego Convention Center, San Diego, CA

About MimiVax: MimiVax is a privately held, clinical-stage immuno-oncology company focused on the development and commercialization of immunotherapeutics and targeted therapies for the treatment of cancer. Our proprietary product portfolio is based on technology licensed from Roswell Park Cancer Institute that targets survivin, a cell-survival protein that is present in most cancers and rarely detectable in normal tissue. Our therapies are designed to break immune tolerance and stimulate immune responses to control tumor growth and recurrence.

About SurVaxM: SurVaxM, our lead immunotherapeutic product, has demonstrated safety and tolerability in a Phase I study in people with malignant gliomas (brain tumors). SurVaxM is currently being evaluated in a Phase II clinical trial in adults with newly diagnosed glioblastoma at five cancer centers: Roswell Park Cancer Institute, Cleveland Clinic, Dana-Farber Cancer Institute, Mass General and Beth Israel Deaconess Hospitals. Also a Phase I clinical trial in combination with REVLIMID® (lenalidomide) as a maintenance therapy for adults with multiple myeloma (a form of blood cancer) is ongoing at Roswell Park.

Read the full story at http://www.prweb.com/releases/mimivax/survaxm/prweb14413751.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. PCI Appoints John Davis, PE, to Board
2. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
3. NeuroVive Appoints Anna Malm Bernsten and Boel Flodgren to its Board of Directors
4. SOTIO a.s. Appoints Chiltern International
5. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
6. California Healthcare Institute Appoints Associate Director, Federal Government Relations and Programs
7. First Warning Systems, Inc., Appoints Veteran Medical Executive Royea as CEO
8. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
9. OHK Medical Devices appoints Mr. Omer Inbar as Chief Executive Officer
10. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
11. TNI BioTech, Inc. Appoints Industry Veteran, Dr. Joseph Fortunak, as a Strategic Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
Breaking Biology Technology:
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
Breaking Biology News(10 mins):